PMID: 19943200Nov 28, 2009Paper

Microbial antitumor drugs: natural products of microbial origin as anticancer agents

Current Opinion in Investigational Drugs
David J Newman, Gordon M Cragg

Abstract

This review discusses the role of microbial secondary metabolites produced by organisms from all three domains of life (the Archaea, Prokarya and Eukarya) as sources of pure natural products or derivatives of natural products, and as leads for novel synthetic compounds that may have the potential to ameliorate cancer. Drugs for which a microbe has either been identified as the producer of the active component or has been associated with its production based on circumstantial evidence are discussed. In addition, the impact of the increase in available genomic information and manipulation is discussed, along with some relevant examples, leading to the realization that the potential of microbes as sources of new leads/agents or as biological probes is large.

Related Concepts

Related Feeds

Archaeogenetics

Recent advances in genomic sequencing has led to the discovery of new strains of Archaea and shed light on their evolutionary history. Discover the latest research on Archaeogenetics here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Journal of Industrial Microbiology & Biotechnology
Lesley-Ann Giddings, David J Newman
Current Opinion in Biotechnology
Amanda L WatersMark T Hamann
Proceedings of the National Academy of Sciences of the United States of America
L Margulis
© 2022 Meta ULC. All rights reserved